Authorship : Guarantor of the article: Quentin M. Anstee. All authors approved the final version of the manuscript. V.R. has received consulting fees from Novo Nordisk, GSK, Boehringer‐Ingelheim, Sagimet, Madrigal, Northsea, LG Pharmaceuticals and ProSciento, and research grants (to institution) from Gilead, Intercept and Merck. A.J.S. consults for and advises Avant Santé and AstraZeneca. A.J.S. also consults for and has received grants from Akero, BMS, Intercept, Eli Lilly, Madrigal and Novo Nordisk. A.J.S. consults for and owns stock in Rivus, and also consults for AGED Diagnostics, Albireo, Alnylam, Altimmune, Boehringer Ingelheim, 89bio, Echosens, Genentech, Gilead, GSK, HistoIndex, Mallinckrodt, Merck, NGM Bio, Novartis, PathAI, Pfizer, Poxel, Regeneron, Salix, Siemens, Surrozen, Takeda, Terns and Zydus. A.J.S. owns stock in Durect, Exalenz, Genfit, Indalo, Inversago and Tiziana, and has received royalties from Elsevier and Wolters Kluwer. V.W.‐S.W. has served as a consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences and TARGET PharmaSolutions, and as a speaker for Abbott, AbbVie, Gilead Sciences, Novo Nordisk and Unilab. He has received a research grant from Gilead Sciences and is a co‐founder of Illuminatio Medical Technology Limited. He has received travel support from AbbVie and Gilead Sciences. Q.M.A. is supported by the NIHR Newcastle Biomedical Research Centre and the Innovative Medicines Initiative (IMI2) of the European Union. He has received consulting fees on behalf of Newcastle University from Alimentiv, Akero, AstraZeneca, Axcella, 89bio, Boehringer Ingelheim, Bristol Myers Squibb, Galmed, Genfit, Genentech, Gilead, GlaxoSmithKline, Hanmi, HistoIndex, Intercept, Inventiva, Ionis, IQVIA, Janssen, Madrigal, Medpace, Merck, NGMBio, Novartis, Novo Nordisk, PathAI, Pfizer, Pharmanest, Prosciento, Poxel, Resolution Therapeutics, Roche, Ridgeline Therapeutics, RTI, Shionogi and Terns. He has received payment or honoraria from Fishawack, Integritas Communications, Kenes, Novo Nordisk, Madrigal, Medscape and Springer Healthcare. L.M.N., C.B., J.F., M.S.K. and N.K. are employees and shareholders of Novo Nordisk A/S.
PubMed
